180 Life Sciences CORP 8-K filings

ETHZilla Corporation will implement a 1-for-10 reverse stock split effective October 20, 2025, to attract institutional investors by increasing its share price.

ETHZilla stockholders approved a significant increase in authorized common stock, new incentive plans, and a director appointment, enhancing corporate flexibility and employee incentives.

ETHZilla Corporation announced its current ETH position and key financial metrics, highlighting its strategy to generate yield through staking and DeFi protocols.

ETHZilla Corporation has secured $350 million in new senior secured convertible notes, amended existing debt terms, and updated its financial position and risk factors.

ETHZilla Corporation announced a new $350 million senior secured convertible debenture, alongside amendments to existing notes and updates on its ETH holdings and stock repurchase program.

ETHZilla Corporation reported the resignation of a director, Stephen H. Shoemaker, and detailed a new executive employment agreement for CEO McAndrew Rudisill.

ETHZilla Corporation announced an update on its stock repurchase program, having bought back 6.0 million shares in September, and detailed its strategy for deploying ETH into Layer 2 protocols to generate yield.

ETHZilla Corporation announced a new $80 million transaction to fund its stock repurchase program, alongside an update on its substantial Ether holdings and a CEO appointment.

ETHZilla Corporation announced the resignation of CEO Blair Jordan, the appointment of McAndrew Rudisill as his successor, and a $1.35 million separation payment.

ETHZilla Corporation announced plans to deploy approximately $100 million in Ether to EtherFi for liquid restaking, aiming to generate higher yields on its treasury holdings.

ETHZilla Corporation announced a $250 million stock repurchase program and updated its Ether accumulation strategy, now holding 102,237 ETH valued at $489 million.

ETHZilla Corporation has entered into an amended sales agreement with Clear Street LLC to offer up to $10 billion in common stock through an at-the-market program, superseding a prior $34.4 million offering.

ETHZilla Corporation secured $156.25 million in senior secured convertible notes, appointed McAndrew Rudisill as Executive Chairman, and granted new stock options and strategic advisor warrants.

ETHZilla Corporation announced the cash exercise of warrants and pre-funded warrants, resulting in the issuance of over 1.9 million new common shares.

ETHZilla Corporation, formerly 180 Life Sciences Corp., announced a strategic rebrand and focus on an Ethereum treasury strategy, backed by a $565 million capital raise.

ETHZilla Corporation filed an amendment to correct share counts from its recent private placement and announced new board appointments.

180 Life Sciences Corp. entered into a Sales Agreement to sell up to $500 million of common stock through an at-the-market offering via Clear Street LLC.

180 Life Sciences Corp. announced a corporate name change to ETHZilla Corporation, a new Nasdaq ticker, and the exercise of warrants generating over $4.5 million in cash.

180 Life Sciences Corp., dba ETHZilla, announced it holds 82,186 ETH with an average acquisition price of $3,806.71, valued at approximately $349 million.

180 Life Sciences Corp. closed a $156.25 million senior secured convertible note offering to boost its Ethereum holdings and announced new strategic advisor warrants and executive stock options.

180 Life Sciences Corp. successfully closed a $425 million private placement, signaling a strategic pivot towards an Ethereum-focused treasury management and digital asset strategy, alongside significant board appointments.

180 Life Sciences Corp. announced a significant strategic shift, raising $425 million through a private placement to establish an Ethereum-focused treasury reserve and plans to rebrand as ETHZilla Corporation.

180 Life Sciences Corp. stockholders approved a significant increase in authorized common shares, new and amended equity incentive plans, and granted the Board authority for a reverse stock split.

180 Life Sciences Corp. announced the accelerated vesting of stock options and restricted stock for its CEO, CAO, and non-executive directors, alongside an extension and increased termination fee for its Chief Accounting Officer's consulting agreement.

180 Life Sciences Corp. announced the grant of a U.S. patent and a Canadian patent allowance for its legacy intellectual property, reinforcing its biotech assets while confirming a strategic pivot to the global iGaming sector.

180 Life Sciences Corp. filed an amendment to its recent 8-K, clarifying executive and director equity awards and compensation terms, alongside the resignation of a board member and the adoption of a new incentive plan.

180 Life Sciences Corp. announced the date for its 2025 Annual Meeting of Shareholders as July 24, 2025, and established key deadlines for shareholder proposals and director nominations.

180 Life Sciences Corp. announced the grant of stock options to key executives and directors for services rendered, alongside a realignment of its Audit and Compensation Committee leadership.

180 Life Sciences Corp. announced significant changes to its executive and director compensation, including a new 2025 Option Incentive Plan, accelerated equity vesting, and an amended CEO consulting agreement, alongside a director's resignation.

180 Life Sciences Corp. announces the receipt of a Notice of Allowance for a U.S. patent covering a novel method to prevent or reduce post-operative cognitive dysfunction.